Immunotherapy plus chemotherapy before surgery for stage II-III lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of an immunotherapy drug (Rilpufan α) with chemotherapy given before surgery for early-stage (stage II-III) non-small cell lung cancer. The goal is to shrink the tumor to make surgery more effective and potentially improve long-term outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with non-small cell lung cancer that is stage II or III (has not spread to other organs).
- You have not received any prior treatment for this cancer (such as surgery, radiation, or chemotherapy).
- If you have a type called adenocarcinoma, you must not have certain genetic mutations (like EGFR or ALK). If you have squamous cell carcinoma, this test is not needed.
- Your overall health is good (able to do daily activities, with adequate blood counts and organ function).
- You must have received two cycles of a specific chemotherapy combination and had at least some shrinkage or stability of the tumor (based on the trial's prior step).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests whether adding adebrelimab (an immunotherapy drug) to standard chemotherapy before surgery can shrink non-small cell lung cancer that can be removed. The goal is to improve the chance of successful surgery and reduce the risk of the cancer coming back.
This study tests whether giving a combination of three medicines before surgery can help shrink tumors in people with stage 2 or 3 non-small cell lung cancer, potentially making surgery and recovery more effective. The medicines include an immunotherapy drug (tislelizumab), a targeted therapy (anlotinib), and a chemotherapy drug (nab-paclitaxel).
This trial tests whether combining a tumor-destroying procedure (ablation) with immunotherapy (tislelizumab) and chemotherapy before surgery can improve outcomes for people with stage II-IIIB non-small cell lung cancer. The goal is to shrink the tumor and boost the immune system to fight the cancer more effectively.
This trial tests whether giving a combination of two immunotherapy drugs (ivonescimab or penpulimab) with chemotherapy before surgery helps shrink tumors and improve outcomes for people with early-stage non-small cell lung cancer. The goal is to make surgery more effective and reduce the chance of cancer coming back.
This trial tests whether combining an immunotherapy drug (adebrelimab or retlirafusp alfa) with another drug (recaticimab) and chemotherapy helps shrink lung cancer before surgery. The goal is to see if this approach improves outcomes for people with resectable non-small cell lung cancer.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.